Insider Transactions Reported by 17 Insiders of NovaBridge Biosciences

Symbol: NBP on Nasdaq
Location: Rockville, MD

Quick Takeaways

NBP - NovaBridge Biosciences has 17 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are available for direct filing-level review.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

NovaBridge Biosciences executives and other stock owners filed with the SEC include:

Name	Relationship	Valuation	Report Date
Chun Kwok Alan Au	Director	Mixed	18 Mar 2026
Robert A. Lenz	Director	Mixed	18 Mar 2026
Ian Ying Woo	Director	Mixed	18 Mar 2026
Adeline Yi Zhang	Global Controller	Mixed	18 Mar 2026
Xin Liu	Director	Mixed	18 Mar 2026
Cong Claire Xu	Senior Vice President, Clinical Development	Mixed	18 Mar 2026
Emmett Cunningham	Director	Mixed	18 Mar 2026
Sean Wuxiong Cao	Chief Business Development Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney, Director	Mixed	18 Mar 2026
Fu Wei	Director	Mixed	18 Mar 2026
Joanna Xuqiong Wu	Officer	Mixed	18 Mar 2026
Ming Kyler Lei	Chief Financial Officer	Mixed	18 Mar 2026
Xiaofan Neo Zhang	Chief Investment Officer	Mixed	18 Mar 2026
Fu Xi-Yong	Chief Executive Officer and Director Exhibit List: Ex. 24.1 - Power of Attorney, Director	Mixed	18 Mar 2026
Liwei Lorraine Lin	General Counsel	Mixed	18 Mar 2026
Phillip Andrew Dennis	Chief Medical Officer	Mixed	18 Mar 2026
Denny Hsueh Wen Chu	EVP, Head of Strategic Partnership Exhibit List: Ex. 24.1 - Power of Attorney	Mixed	18 Mar 2026
Conor Chia-Hung Yang	Director	Mixed	18 Mar 2026

Top shareholders of NovaBridge Biosciences (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
CBC Investment I-Mab Ltd	13D/G	Wei Fu	12%	30,499,709	$121,227,193	+$11,952,376	29 Jan 2026	13D/G
Everest Medicines Ltd	13D/G	Everest Medicines Limited	16%	42,524,716	$90,577,645	$0	05 Aug 2025	13D/G
JANUS HENDERSON GROUP PLC	13F	Company	3.2%	8,436,641	$33,577,831	—	31 Dec 2025	13F
HHLR ADVISORS, LTD.	13F	Company	2.3%	5,980,568	$23,802,661	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	1.4%	3,785,502	$15,066,298	—	31 Dec 2025	13F
Siren, L.L.C.	13F	Individual	1.1%	3,000,000	$11,940,000	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	0.87%	2,298,501	$9,148,034	—	31 Dec 2025	13F
Ariose Capital Management Ltd	13F	Company	0.51%	1,363,515	$5,426,790	—	31 Dec 2025	13F
S.c.a. Candriam	13F	Individual	0.43%	1,132,563	$4,507,793	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.4%	1,050,000	$4,179,000	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.38%	1,000,000	$3,980,000	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.32%	846,008	$3,367,112	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.24%	628,923	$2,503,113	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.23%	618,347	$2,461,021	—	31 Dec 2025	13F
Exome Asset Management LLC	13F	Company	0.19%	499,587	$1,988,356	—	31 Dec 2025	13F
AIHC Capital Management Ltd	13F	Company	0.16%	413,979	$1,647,636	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.14%	359,878	$1,432,314	—	31 Dec 2025	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.07%	191,714	$763,022	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.07%	181,776	$723,468	—	31 Dec 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.06%	148,452	$590,839	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.05%	140,946	$560,965	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.05%	140,867	$560,651	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.05%	131,830	$524,683	—	31 Dec 2025	13F
Taikang Asset Management (Hong Kong) Co Ltd	13F	Company	0.05%	128,765	$512,485	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.04%	116,705	$464,486	—	31 Dec 2025	13F
ALPS ADVISORS INC	13F	Company	0.04%	112,451	$447,555	—	31 Dec 2025	13F
DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.	13F	Company	0.03%	80,400	$319,992	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.02%	47,479	$188,966	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.02%	45,084	$179,434	—	31 Dec 2025	13F
SG Americas Securities, LLC	13F	Company	0.01%	36,481	$145,000	—	31 Dec 2025	13F
NOMURA HOLDINGS INC	13F	Company	0.01%	35,200	$140,096	—	31 Dec 2025	13F
Squarepoint Ops LLC	13F	Company	0.01%	34,322	$136,602	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.01%	32,581	$129,673	—	31 Dec 2025	13F
Quadrature Capital Ltd	13F	Company	0.01%	29,588	$117,760	—	31 Dec 2025	13F
MANGROVE PARTNERS IM, LLC	13F	Company	0.01%	26,026	$103,583	—	31 Dec 2025	13F
Leonteq Securities AG	13F	Company	0.01%	21,000	$83,580	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.01%	20,403	$81,204	—	31 Dec 2025	13F
China Universal Asset Management Co., Ltd.	13F	Company	0.01%	16,940	$67,421	—	31 Dec 2025	13F
Brooklyn Investment Group	13F	Company	0%	12,715	$51,242	—	31 Dec 2025	13F
Freestone Capital Holdings, LLC	13F	Company	0%	10,000	$39,800	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	8,219	$32,711	—	31 Dec 2025	13F
Mirae Asset Global Investments Co., Ltd.	13F	Company	0%	7,583	$30,180	—	31 Dec 2025	13F
ROYAL BANK OF CANADA	13F	Company	0%	6,360	$25,000	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0%	6,039	$24,035	—	31 Dec 2025	13F
GROUP ONE TRADING LLC	13F	Company	0%	3,963	$15,773	—	31 Dec 2025	13F
SIMPLEX TRADING, LLC	13F	Company	0%	3,060	$12,178	—	31 Dec 2025	13F
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	13F	Company	0%	2,947	$11,729	—	31 Dec 2025	13F
GF FUND MANAGEMENT CO. LTD.	13F	Company	0%	2,042	$8,127	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	1,765	$7,025	—	31 Dec 2025	13F
JONES FINANCIAL COMPANIES LLLP	13F	Company	0%	1,104	$4,394	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for NovaBridge Biosciences

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Shares Owned	Date	Ownership
Cong Claire Xu	NBP	Ordinary Shares	284,266	18 Mar 2026	Direct
Phillip Andrew Dennis	NBP	Ordinary Shares	142,740	18 Mar 2026	Direct
Fu Xi-Yong	NBP	Ordinary Shares	59,823	18 Mar 2026	Direct
Xiaofan Neo Zhang	NBP	Ordinary Shares	874,000	18 Mar 2026	Direct
Joanna Xuqiong Wu	NBP	Ordinary Shares	4,600	18 Mar 2026	Spouse
Joanna Xuqiong Wu	NBP	Ordinary Shares	1,150	18 Mar 2026	Direct
Fu Wei	NBP	Ordinary Shares	7,129,885	18 Mar 2026	By Nova Aqua Limited
Fu Wei	NBP	Ordinary Shares	2,369,546	18 Mar 2026	By C-Bridge II Investment Ten Limited
Fu Wei	NBP	Ordinary Shares	5,574,560	18 Mar 2026	By CBC SPVII Limited
Fu Wei	NBP	Ordinary Shares	3,641,544	18 Mar 2026	By IBC Investment Seven Limited
Fu Wei	NBP	Ordinary Shares	11,784,164	18 Mar 2026	By CBC Investment l-Mab Limited
Sean Wuxiong Cao	NBP	Ordinary Shares	56,472	18 Mar 2026	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.